The effect and relative importance of sleep disorders for all-cause mortality in middle-aged and older asthmatics

BMC Geriatrics

Table 3 Dose-dependent analyses of the associations between sleep disorders and all-cause mortality among study population with asthma

	Model 1	P	Model 2	P	Model 3	P
Excessive daytime sleepiness
Normal	Ref		Ref		Ref
Mild	1.87(0.85, 4.12)	0.12	1.69(0.73, 3.88)	0.22	2.05(0.83, 5.03)	0.12
Moderate	0.44(0.12, 1.63)	0.22	0.47(0.13, 1.75)	0.26	0.57(0.14, 2.27)	0.43
Severe	2.17(0.91, 5.15)	0.08	2.78(1.11, 6.86)	0.03	3.08(1.11, 8.56)	0.03
Probable insomnia
No vs yes	0.48(0.17, 1.37)	0.17	0.37(0.12, 1.14)	0.08	0.28(0.08, 1.00)	0.05
Obstructive sleep apnea
Normal	Ref		Ref		Ref
Mild	1.19(0.61, 2.33)	0.62	0.94(0.45, 1.97)	0.88	0.97(0.41, 2.27)	0.94
Moderate	1.54(0.66, 3.58)	0.31	1.83(0.77, 4.38)	0.17	1.55(0.5, 4.75)	0.45
Severe	0.79(0.26, 2.44)	0.68	0.57(0.17, 1.88)	0.36	0.44(0.1, 1.92)	0.27
Objective sleep duration
Very short	Ref		Ref		Ref
Short	0.46(0.24, 0.88)	0.02	0.43(0.21, 0.88)	0.02	0.44(0.21, 0.94)	0.03
Relatively healthy	0.25(0.12, 0.52)	< 0.01	0.22(0.10, 0.50)	< 0.01	0.25(0.09, 0.69)	< 0.01
Healthy	0.23(0.08, 0.65)	< 0.01	0.15(0.05, 0.39)	< 0.01	0.19(0.05, 0.69)	0.01

Note: Model1 included sex, age, race, smoking status, coffee consumption, BMI, excessive daytime sleepiness, probable insomnia, obstructive sleep apnea and objective sleep duration.
Model 2 = Model 1+ diabetes, hypertension, angina, myocardial infarction, COPD, high cholesterol, drugs use (benzodiazepines, tricylic anti-depressants and non-tricylic anti-depressants), inhaled steroids for asthma, asthmatic attack.
Model 3 = Model 2 + FEV1, FEV1/FVC, wake after sleep onset, sleep efficiency, TIMEREMP, T90.

ISSN: 1471-2318